Kara Cooper Gilmer
Family · Anderson, SCNPI 1437387354
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $107,825 of the $127,345 with a category attached, or 84.7%. AbbVie accounts for 96.0% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $53,311, 6.5 times the $8,205 reported in 2021. Among family clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $218.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$122K
- Lilly USA, LLC$503
- Teva Pharmaceuticals USA, Inc.$432
- Neurocrine Biosciences, Inc.$409
- Acadia Pharmaceuticals Inc$364
- Novartis$307
- plus $3K from 29 others
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$107,82585%
- Travel & lodging$10,2898%
- Food & beverage$9,0737%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 336 | $122,313 |
| Lilly USA, LLC | 37 | $503 |
| Teva Pharmaceuticals USA, Inc. | 29 | $432 |
| Neurocrine Biosciences, Inc. | 19 | $409 |
| Acadia Pharmaceuticals Inc | 19 | $364 |
| Novartis | 15 | $307 |
| EMD Serono, Inc. | 12 | $280 |
| Eisai Inc. | 13 | $251 |
| Biogen | 3 | $202 |
| Catalyst Pharmaceuticals, Inc. | 8 | $186 |
| Argenx US, Inc. | 6 | $186 |
| UCB, Inc. | 7 | $185 |
| Pfizer | 9 | $175 |
| AstraZeneca | 6 | $166 |
| Genentech USA, Inc. | 7 | $162 |
| TG Therapeutics, Inc. | 7 | $150 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Amgen(2 entities) | 6 | $129 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $105 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Lundbeck LLC | 4 | $69 |
| Amneal Pharmaceuticals LLC | 3 | $64 |
| MDD US Operations, LLC | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 2 | $62 |
| Mallinckrodt Hospital Products Inc. | 2 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Sanofi | 1 | $43 |
| Livanova USA, Inc. | 2 | $42 |
| Neurelis, Inc. | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| CSL Behring | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Bristol Myers Squibb | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$127,345 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 105 | $168,807 |
| QuliptaAtogepant | 66 | $107,121 |
| AubagioTeriflunomide | 11 | $102,395 |
| FingolimodFingolimod Hcl | 34 | $91,526 |
| Aimovig AutoinjectorErenumab-Aooe | 80 | $73,667 |
| Emgality PenGalcanezumab-Gnlm | 89 | $71,095 |
| Nurtec OdtRimegepant Sulfate | 29 | $56,407 |
| FycompaPerampanel | 41 | $51,465 |
| Keppra XrLevetiracetam | 12 | $22,067 |
| KeppraLevetiracetam | 12 | $13,391 |
| Levetiracetam | 343 | $13,098 |
| Tegretol XrCarbamazepine | 17 | $12,587 |
| Carbamazepine ErCarbamazepine | 41 | $5,656 |
| Lamotrigine ErLamotrigine | 12 | $5,579 |
| Divalproex Sodium | 49 | $5,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $122,313 | $275,928171 claims |
| SanofiAubagio | $43 | $102,39511 claims |
| PfizerNurtec Odt | $175 | $56,40729 claims |
| Eisai Inc.Fycompa | $251 | $51,46541 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $64 | $1,73619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Anderson
- Nancy RichmondAnderson$21K
- Margaret KelleyAnderson$12K
- Lisa CobbAnderson$11K
- Sarah HambyAnderson$10K
- Sara ChristieGreenville$229K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.